Skip to search formSkip to main contentSkip to account menu

gp100:209-217 Peptide

Known as: G9-209 
A synthetic peptide vaccine consisting of the amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with… 
National Institutes of Health

Related topics

Related topics

6 relations
Antigen SensitizationCytotoxic T-LymphocytesMelanoma CellT-Cell Activation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines
Efforts to develop effective cancer vaccines often use combinations of immunogenic peptides to increase the applicability and… 
Highly Cited
2004
Highly Cited
2004
Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination
Successful immunotherapy with peptide vaccines depends on the in vivo generation of sufficient numbers of anti-tumor T cells with… 
Review
1999
Review
1999
Cancer immunotherapy: is there real progress at last?
This review summarises the evolution of recent major advances in cancer immunotherapy, using metastatic melanoma as a model. The… 
Review
1999
Review
1999
Cancer Immunotherapy
This review summarises the evolution of recent major advances in cancer immunotherapy, using metastatic melanoma as a model. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)